|
Market Cap (25-Jun) $125,067,280 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.07 |
ATH released this announcement to the ASX on 13 November 2020, 15:04. The announcement is not marked as price sensitive, and is 15 page(s) in length and 525.91kb in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.368% short sold according to ASIC data. It was ranked the 317th most shorted stock on the ASX. It remains ranked 426th as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| Becoming a substantial holder | 13 November 2020, 15:04 |
| Appendix 4C and Quarterly Cash Flow Report | 30 October 2020, 9:34 |
| MSA patients enrolled in bioMUSE Study | 27 October 2020, 9:21 |
| Change in substantial holding | 27 October 2020, 8:16 |
You must be logged in to post a reply.
Alterity Therapeutics 